Background: The most common acid known abnormality is gastroesophageal reflux disease [GERD] which is treated by proton pump inhibitors [PPIs]. One of new family of gastric acid-suppressing medications is Vonoprazan that works as a potassium-competitive acid blocker [P-CABs].
Aim of the Work: To compare the effectiveness of 20 mg vonoprazan versus omeprazole 40 mg once daily half an hour before breakfast as a treatment of symptoms and mucosal healing in GERD patients.
Patients and Methods: Sixty cases were enrolled in a comparative clinical study included 60 patients proven to have GERD after having upper endoscopes were classified into two groups 30 patients each, group [A] on Omeprazole 40 mg once daily, whereas group [B] on Vonoprazan 20 mg once daily for 8 weeks then reevaluation in both groups by symptoms relief using GERD Q score, frequency scale of the symptoms of gastroesophageal reflux disease questionnaire [FSSG]  and upper endoscopy was done for all patients after 8 weeks. For each patient medical history taking, clinical examination, routine laboratory investigations, and upper endoscopy with GERD classification according to LA classification were done for all patients.
Results: No detected differences between the included groups in GERD Q Score and FSSG score. Our data showed that complete symptoms resolution was somewhat higher among the Omeprazole group compared to the Vonoprazan group without a statistically significant difference. There is a significant decrease in reflux score, and total score in both groups however, the drop in FSSG scores was more significant in group A in comparison to group B.
Conclusion: Vonoprazan showed no superiority over omeprazole in relief of typical symptoms and mucosal healing in patients with GERD, the drop in FSSG scores was more significant in Omeprazole group compared to Vonoprazan group.